Although evidence-based therapies such as antiplatelet agents, high-intensity statins, beta-blockers, and ACE inhibitors are proven to be effective in both sexes, females are less likely than males to receive these medications or invasive interventions despite often presenting later and with a greater comorbidity burden [19]. Tailoring therapy to individual risk factors and physiological responses is essential, especially in young women (<55 years old) who are seeing a rise in acute MI rates from 21% to 31% in a 10-year period [19]. Here, ACE is linked to myocardial infarction.